The liposome development and manufacturing services market is anticipated to grow at a CAGR of nearly 10% till 2035, claims Roots Analysis.
Driven by the development of advanced methods for preparation and characterization of liposomes, and the application of these molecules in therapeutics and diagnostics, the demand for liposomes is expected to rise in the coming years
Despite the growing interest in liposome-based therapeutics and diagnostics, the development and manufacturing of liposomes is associated with several challenges, including complex manufacturing processes, huge capital investments, inadequate clinical grade production and GMP compliant industrial scale-up, lack of facilities with necessary infrastructure, as well as concerns related to storage and stability.
In order to deal with the aforementioned challenges, a number of pharmaceutical companies have demonstrated the preference to outsource their respective liposome development and manufacturing operations to specialized service providers.
Key Market Insights
More than 70 companies are currently offering services related to liposome development and manufacturing, globally
Majority (74%) of the service providers offer formulation development services for liposomes. This is followed by players offering analytical method development (65%), liposome contract manufacturing (64%), and process development (61%) services.
Close to 6,100 articles focused on liposomes, have been published in reputed scientific journals, since 2017
More than 50% of the articles focused on liposomes were published post-2019. Popular journals that have published multiple articles include International Journal of Pharmaceutics, Journal of Controlled Release, and Pharmaceutics.
More than 800 clinical trials have been registered for the evaluation of liposome-based therapeutics, worldwide
The clinical research activity, in terms of number of trials registered, is reported to have increased at a CAGR of 17%, during the period 2017–2021. Of the total number of trials registered, 60% have already been completed, while 26% of the studies are actively recruiting participants.
Nearly 700 patents related to liposomes have been filed / granted, since 2017
Owing to the increase in research and development efforts led by several industry and non-industry players engaged in this domain, close to 55% of patent applications have been filed post-2016. It is worth noting that 61% of patents related to liposomes were filed / granted in the US alone.
Over 110 global events related to liposomes were organized in the past couple of years
Majority (63%) of the events related to liposomes, were organized virtually in order to comply with the guidelines in the ongoing COVID-19 pandemic. Further, the agendas of the events organized post-2020 include discussions on the applications, and recent advancements in technologies associated with liposomes.
Go / No-Go framework can be used to assist players in the crucial outsourcing decision-making process
The framework enables evaluation of the current capabilities of liposome-based therapeutic developers, based on 4+ parameters, including trial phase, target therapeutic area, location of trial(s), patient enrollment and willingness to outsource.
Despite the growing interest in liposome-based therapeutics and diagnostics, the development and manufacturing of liposomes is associated with several challenges, including complex manufacturing processes, huge capital investments, inadequate clinical grade production and GMP compliant industrial scale-up, lack of facilities with necessary infrastructure, as well as concerns related to storage and stability.
In order to deal with the aforementioned challenges, a number of pharmaceutical companies have demonstrated the preference to outsource their respective liposome development and manufacturing operations to specialized service providers.
The financial opportunity within the liposome development and manufacturing services market has been analyzed across the following segments:
Type of Product Formulation
- Therapeutic
- Nutraceutical
Scale of Operation
- Discovery / Research
- Preclinical
- Clinical
- Commercial
End User
- Pharmaceutical and Biotechnology Industry
- Cosmetic Industry
- Food Industry
- Agricultural Industry
- Academics
- Other Industries
Key Geographical Regions
- North America
- Europe
- Asia-Pacific
- Middle East and North Africa
- Latin America
The Liposome Development and Manufacturing Services Market, 2022–2035 report features the following companies, which we identified to be key players in this domain:
- Baxter BioPharma Solutions
- Charles River Laboratories
- Evonik
- Fresenius Kabi
- Fujifilm
- GEA
- Intertek
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]
Contact Information:
Roots Analysis Private Limited
Ben Johnson
+1 (415) 800 3415
